RESUMEN
BACKGROUND: Cognitive impairment is a core feature of schizophrenia with unclear mechanisms, particularly neurocognition. The objective of this study was to investigate the association between duration of untreated psychosis (DUP) and neurocognition, as well as potential biological mechanisms. METHODS: A total of 219 patients were recruited in this study. DUP was measured in years, reflecting the untreated period. Neurocognition was assessed by the MATRICS Consensus Cognitive Battery (MCCB). The plasma concentrations of three growth factors, vascular endothelial growth factor (VEGF), brain-derived neurotrophic factor (BDNF), and epidermal Growth Factor (EGF) were detected by enzyme-linked immunosorbent assay in 128 patients. Multiple linear regression analysis was used to analyze the association between DUP, growth factors, and neurocognition. RESULTS: Our findings showed that DUP was significantly negatively correlated with speed of processing and reasoning and problem-solving in all patients (N = 219, P < 0.05). Five years was defined as cut-off point for long and short DUP group in the present study. Only in the short DUP patients, DUP was strongly associated with visual learning and neurocognition (P < 0.05). In patients with growth factor (N = 128), DUP was independently associated with speed of processing, verbal learning, and neurocognition (P < 0.05). Further, plasma concentrations of VEGF, BDNF, and EGF were all significantly correlated with neurocognition (P < 0.05). Additionally, we found a potential trend of correlation between DUP and BDNF (P = 0.061). CONCLUSION: Our study provides insights into a negative correlation between DUP and neurocognition, and BDNF may serve as a potential biological mechanism.
RESUMEN
OBJECTIVE: Schizophrenia (SCZ) is a severe psychiatric disorder with unknown etiology and lacking specific biomarkers. Herein, we aimed to explore plasma biomarkers relevant to SCZ using targeted metabolomics. METHODS: Sixty drug-naïve SCZ patients and 36 healthy controls were recruited. Psychotic symptoms were assessed using the Positive and Negative Syndrome Scale. We analyzed the levels of 271 metabolites in plasma samples from all subjects using targeted metabolomics, and identified metabolites that differed significantly between the two groups. Then we evaluated the diagnostic power of the metabolites based on receiver operating characteristic curves, and explored metabolites associated with the psychotic symptoms in SCZ patients. RESULTS: Twenty-six metabolites showed significant differences between SCZ patients and healthy controls. Among them, 12 metabolites were phosphatidylcholines and cortisol, ceramide (d18:1/22:0), acetylcarnitine, and γ-aminobutyric acid, which could significantly distinguish SCZ from healthy controls with the area under the curve (AUC) above 0.7. Further, a panel consisting of the above 4 metabolites had an excellent performance with an AUC of 0.867. In SCZ patients, phosphatidylcholines were positively related with positive symptoms, and cholic acid was positively associated with negative symptoms. CONCLUSION: Our study provides insights into the metabolite alterations associated with SCZ and potential biomarkers for its diagnosis and symptom severity assessment.
